Mylan 'tip of the iceberg,' senator says as report suggests drug misclassifications cost taxpayers billions

Taxpayers may have lost billions because drugs were potentially misclassified under the Medicaid Drug Rebate Program, according to a new report released by the Health and Human Services Office of Inspector General. The OIG report, which analyzed the years 2012-2016, indicated that the top 10 potentially misclassified drugs cost Medicaid $1.3 billion.That’s the same amount that a prior report said cost taxpayers over 10 years due to Mylan NV’s misclassification of EpiPen. Mylan (Nasdaq:MYL),…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news